



Company

Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech, high-tech, IT and telecom. The services are provided in the form of independent reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Zurich, Munich and North America, Venture Valuation comprises experts in finance, biotechnology, pharma and high technology industries.

Services

Since 1999 Venture Valuation has already worked with over 70 high growth companies and several venture funds providing the following products:

- 1) **Valuation Report:** a comprehensive analysis using soft factors such as experience of management, assessment of scientific and technological quality, intellectual property status as well as factors such as market developments. At the same time the report helps to highlight critical factors, which will drive company value in the long-term.
- 2) **Valuation Radar:** is a monitoring instrument tailored to venture capital funds who wish to have an independent and comprehensive comparative assessment of their portfolio companies. Each company in the fund's portfolio is assessed using Venture Valuation's standard methodologies and common criteria. This allows funds to monitor portfolio value using a common valuation assessment. Valuation Radar is most effective when employed on an ongoing basis.

Venture Valuation's cutting edge financial valuation methodology is tailored to high growth companies and is based on research carried out at the University of St. Gallen, Switzerland (HSG) and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL), two of the world's leading financial research and teaching centers.

Clients

High growth companies planning a new round of financing, a merger or an acquisition and wishing to establish an independent, third party valuation of their enterprise. A pre-financing valuation report from an independent third party such as Venture Valuation provides an invaluable tool in the hands of an emerging enterprise to successfully complete financing rounds at all stages of investment and provides a strong basis for negotiations.

Investors (such as the Novartis Venture Fund) wishing to re-value or monitor an existing portfolio, track company performance/progress or get an external opinion before making a new investment. We tailor our products to your needs and price our services competitively.

Contacts

Switzerland / Europe

Patrik Frei, Partner & CEO
Phone: +41 (43) 321 86 60
patrik.frei@venturevaluation.ch

North America

Dr. Susanne Acklin, Partner
Phone: +1 (519) 495 5449
s.e.acklin@venturevaluation.com

Venture Valuation

Badenerstr. 18 | 8004 Zurich | Switzerland | Phone +41 (43) 321 86 60
Fax +41 (43) 321 86 61 | info@venturevaluation.ch | www.venturevaluation.com